These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37455595)

  • 1. Reply to letter by Hadigal et al. regarding the cost-effectiveness of high dose quadrivalent vaccine in three European countries.
    Alvarez FP; Bricout H; Marques C; Soininen A; Sainio T; Petit C; de Courville C; Chevalierf P
    J Med Econ; 2023; 26(1):1167-1168. PubMed ID: 37455595
    [No Abstract]   [Full Text] [Related]  

  • 2. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine.
    Drolet M; Laprise JF; Boily MC; Franco EL; Brisson M
    Int J Cancer; 2014 May; 134(9):2264-8. PubMed ID: 24174175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
    Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
    Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
    Lee VJ; Tay SK; Teoh YL; Tok MY
    BMC Public Health; 2011 Mar; 11():203. PubMed ID: 21453537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and cost-effectiveness of human papillomavirus vaccination strategies among men who have sex with men in China: a modeling study.
    Li Y; Lin YF; Wu X; Zhou X; Tian T; Guo Z; Fu L; Yang L; Lu Z; Fan S; Lu Y; Ke W; Zou H
    Front Immunol; 2023; 14():1197191. PubMed ID: 37426648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Benefit Analysis of Human Papillomavirus Vaccine in Iran.
    Sargazi N; Takian A; Daroudi R; Nahvijou A; Yaseri M; Ghanbari Motlagh A; Zendehdel K
    J Prev (2022); 2022 Dec; 43(6):841-857. PubMed ID: 35916995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model.
    Jit M; Chapman R; Hughes O; Choi YH
    BMJ; 2011 Sep; 343():d5775. PubMed ID: 21951758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
    Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
    Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
    Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reply to letter to editor by Hadigal et al. regarding the immunogenicity and safety trial of high-dose influenza vaccine in adults aged ≥60 years.
    Yin JK; Pepin S; van Aalst R; Loiacono MM; Samson SI
    Hum Vaccin Immunother; 2022 Nov; 18(6):2106749. PubMed ID: 35914122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effectiveness and cost-effectiveness of quadrivalent human papillomavirus vaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasia.
    Deshmukh AA; Chiao EY; Das P; Cantor SB
    Vaccine; 2014 Dec; 32(51):6941-6947. PubMed ID: 25444820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reply letter to "Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial".
    Hadigal S; Colombo L; Haughie S
    Hum Vaccin Immunother; 2022 Nov; 18(5):2085470. PubMed ID: 35674507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
    Annemans L; Rémy V; Oyee J; Largeron N
    Pharmacoeconomics; 2009; 27(3):231-45. PubMed ID: 19354343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries.
    Kiatpongsan S; Kim JJ
    PLoS One; 2014; 9(9):e106836. PubMed ID: 25198104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model.
    Jit M; Brisson M; Laprise JF; Choi YH
    BMJ; 2015 Jan; 350():g7584. PubMed ID: 25567037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
    Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination.
    Joshi S; Anantharaman D; Muwonge R; Bhatla N; Panicker G; Butt J; Rani Reddy Poli U; Malvi SG; Esmy PO; Lucas E; Verma Y; Shah A; Zomawia E; Pimple S; Jayant K; Hingmire S; Chiwate A; Divate U; Vashist S; Mishra G; Jadhav R; Siddiqi M; Sankaran S; Pillai Rameshwari Ammal Kannan T; Kartha P; Shastri SS; Sauvaget C; Radhakrishna Pillai M; Waterboer T; Müller M; Sehr P; Unger ER; Sankaranarayanan R; Basu P
    Vaccine; 2023 Jan; 41(1):236-245. PubMed ID: 36446654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
    Cleemput I; Thiry N
    Pharmacoeconomics; 2009; 27(5):433; author reply 433-4. PubMed ID: 19586082
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
    Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
    Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
    Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
    J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.